<p>根据 Oppenheimer &amp; Co. Inc.在最近向 SEC 提交的 13F 表格，该公司在第四季度购买了 Axsome Therapeutics, Inc.（NASDAQ:AXSM - 免费报告）的新股份。该基金购买了 7,076 股公司股票，价值约为 1,292,000 美元。</p>
<ul>
<li>生物科技正在升温——这两只热门股票脱颖而出</li>
</ul>
<p>其他大型投资者也买卖了该公司的股票。M&amp;T Bank Corp 在第四季度将其在 Axsome Therapeutics 的持股增加了 37.3%。M&amp;T Bank Corp 现在拥有 2,560 股公司股票，价值 467,000 美元，此前在上个季度又购买了 696 股。Pictet Asset Management Holding SA 在第四季度将其在 Axsome Therapeutics 的持仓增加了 20.4%。Pictet Asset Management Holding SA 现在拥有 436,063 股公司股票，价值 79,643,000 美元，此前在上个季度又购买了 73,925 股。UBS Group AG 在第四季度将其在 Axsome Therapeutics 的股份增加了 67.2%。UBS Group AG 现在拥有 355,318 股公司股票，价值 64,895,000 美元，此前在上个季度又购买了 142,867 股。Concurrent Investment Advisors LLC 在第四季度获得了 Axsome Therapeutics 的新股份，价值约为 300,000 美元。最后，HB Wealth Management LLC 在第四季度将其在 Axsome Therapeutics 的股份增加了 136.7%。HB Wealth Management LLC 现在拥有 34,102 股公司股票，价值 6,228,000 美元，此前在上个季度又购买了 19,696 股。81.49% 的股票由机构投资者和对冲基金持有。</p>
<p>获取 <strong>Axsome Therapeutics</strong> 的提醒：</p>
<h2>Axsome Therapeutics 新闻汇总</h2>
<p>以下是本周影响 Axsome Therapeutics 的关键新闻：</p>
<ul>
<li>积极情绪：强劲的商业吸引力——Axsome 报告第一季度产品收入为 1.912 亿美元，同比增长约 57%，得益于 AUVELITY 和 SUNOSI，这支持了公司的增长叙述和近期现金生成。阅读更多。</li>
<li>积极情绪：分析师乐观和目标价上调——多家机构提高了目标价（尤其是瑞穗证券至 310 美元，富国银行至 255 美元，贝尔德等），覆盖仍然偏向积极，这可以支持上涨势头和买入兴趣。阅读更多。</li>
<li>中性情绪：管理层外联安排——Axsome 将参加 5 月的投资者会议（包括美银的炉边聊天），提供额外的投资者接触，但不确定立即影响。阅读更多。</li>
<li>中性情绪：财报细节和电话会议记录可用——分析师正在解析电话会议和指导的影响；更深入的阅读可能会解决关于销售节奏和费用轨迹的问题。阅读更多。</li>
<li>消极情绪：盈利未达预期——GAAP 每股收益为（1.26 美元），未达到市场共识（约 0.85 美元的亏损），负毛利率/股本回报率突显了近期盈利能力和成本结构的担忧，尽管收入强劲。阅读更多。</li>
<li>消极情绪：内部人士出售——首席运营官 Mark Jacobson 披露了销售（5 月 4 日的大宗交易和 5 月 5 日的小额交易），这可能会引发短期情绪问题，尽管报告者表示仍持有股份。阅读更多。</li>
<li>消极情绪：耐久性担忧——一些分析师/评论员质疑连续产品销售趋势和峰值收入假设的可实现性，这可能会抑制多重扩张，除非有更明确的毛利改善。阅读更多。</li>
</ul>
<h2>分析师评级变动</h2>
<ul>
<li>5 只医疗股票的收益增长超过三位数</li>
</ul>
<p>几家研究公司最近对 AXSM 发表了看法。Jefferies Financial Group 将 Axsome Therapeutics 的目标价从 245.00 美元上调至 275.00 美元，并在周一的报告中给予该公司 “买入” 评级。Cantor Fitzgerald 在周一的研究报告中重新发布了 “增持” 评级，并设定了 272.00 美元的目标价。Truist Financial 在 3 月 25 日的研究报告中将 Axsome Therapeutics 的评级提升至 “强力买入”。Oppenheimer 在周一的研究报告中设定了 280.00 美元的目标价。最后，Needham &amp; Company LLC 将 Axsome Therapeutics 的目标价从 225.00 美元上调至 255.00 美元，并在周二的报告中给予该股票 “买入” 评级。一位研究分析师给予该股票 “强力买入” 评级，十八位给予 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，共识目标价为 251.26 美元。</p>
<p><strong>查看我们最新的 AXSM 股票报告</strong></p>
<h2>Axsome Therapeutics 股价下跌 0.2%</h2>
<ul>
<li>struggling Axsome 股票可能因药物试验成功而反弹</li>
</ul>
<p>NASDAQ:AXSM 周四开盘价为 222.63 美元。Axsome Therapeutics, Inc.的 52 周低点为 96.09 美元，52 周高点为 234.29 美元。该公司的债务与股本比率为 2.27，速动比率为 1.48，流动比率为 1.39。该公司的 50 日移动平均线为 172.69 美元，200 日移动平均线为 164.03 美元。该公司的市值为 114.6 亿美元，市盈率为-59.69，贝塔值为 0.59。</p>
<p>Axsome Therapeutics（NASDAQ:AXSM - 获取免费报告）最后一次公布财报是在 5 月 4 日，周一。该公司报告本季度每股收益为（1.26 美元），未达到分析师的共识预期（0.85 美元的亏损），差距为（0.41 美元）。该公司本季度的收入为 1.912 亿美元，而市场共识预期为 1.911 亿美元。Axsome Therapeutics 的股本回报率为负 267.16%，净利润率为负 26.59%。Axsome Therapeutics 的收入同比增长 57.4%。股票分析师预计 Axsome Therapeutics, Inc.在本年度将发布-1.19 的每股收益。</p>
<h2>Axsome Therapeutics 的内部交易</h2>
<p>在其他新闻中，内部人士 Ari Maizel 在 2023 年 4 月 22 日的交易中出售了 7,500 股公司的股票。股票的平均售价为 182.42 美元，总价值为 1,368,150.00 美元。交易后，该内部人士直接持有 7,500 股公司股票，价值为 1,368,150 美元。此次交易使其持股减少了 50.00%。该出售在向证券交易委员会提交的文件中披露，相关文件可通过此链接获取。此外，首席运营官 Mark L. Jacobson 在 2023 年 2 月 26 日的交易中出售了 35,378 股公司的股票。这些股票的平均售价为 161.88 美元，总价值为 5,726,990.64 美元。关于此次出售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士共出售了 72,628 股公司股票，价值为 12,205,662 美元。公司内部人士持有 20.60% 的公司股票。</p>
<h2>关于 Axsome Therapeutics</h2>
<p>（免费报告）</p>
<p>Axsome Therapeutics, Inc 是一家临床阶段的生物制药公司，致力于开发针对中枢神经系统（CNS）疾病的新疗法。该公司专注于小分子药物，旨在满足抑郁症、偏头痛、嗜睡症和纤维肌痛等领域的未满足医疗需求。Axsome 采用精准医学的方法，利用药理创新来针对疾病的潜在机制，提高患者的治疗效果。</p>
<p>Axsome 的产品管线包括多个晚期和已批准的产品候选者。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们认为比 Axsome Therapeutics 更好的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Axsome Therapeutics 吗？</h2>
<p>在你考虑 Axsome Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Axsome Therapeutics 并不在名单上。</p>
<p>虽然 Axsome Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AXSM

<p>Oppenheimer & Co. Inc. 在第四季度新建了 Axsome Therapeutics 的持仓，购买了 7,076 股，价值约 129 万美元。其他投资者，包括 M&T Bank Corp 和 UBS Group AG，也增加了对该公司的投资。尽管收入增长强劲，Axsome 仍面临盈利未达预期和内部人士抛售等挑战，这可能影响投资者情绪。分析师们依然乐观，多位分析师上调了目标价，并维持对该股票的积极评级，该股票的共识评级为 “适度买入”</p>

<p>Oppenheimer &amp; Co. Inc. purchased a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 7,076 shares of the company's stock, valued at approximately $1,292,000.</p>
<div class="lb-trans"><p>根据 Oppenheimer &amp; Co. Inc.在最近向 SEC 提交的 13F 表格，该公司在第四季度购买了 Axsome Therapeutics, Inc.（NASDAQ:AXSM - 免费报告）的新股份。该基金购买了 7,076 股公司股票，价值约为 1,292,000 美元。</p>
</div><ul>
<li>Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技正在升温——这两只热门股票脱颖而出</li>
</ul>
</div><p>Other large investors have also bought and sold shares of the company. M&amp;T Bank Corp lifted its holdings in shares of Axsome Therapeutics by 37.3% in the fourth quarter. M&amp;T Bank Corp now owns 2,560 shares of the company's stock worth $467,000 after acquiring an additional 696 shares during the last quarter. Pictet Asset Management Holding SA increased its position in Axsome Therapeutics by 20.4% during the 4th quarter. Pictet Asset Management Holding SA now owns 436,063 shares of the company's stock worth $79,643,000 after purchasing an additional 73,925 shares in the last quarter. UBS Group AG lifted its stake in Axsome Therapeutics by 67.2% in the 4th quarter. UBS Group AG now owns 355,318 shares of the company's stock valued at $64,895,000 after purchasing an additional 142,867 shares during the last quarter. Concurrent Investment Advisors LLC acquired a new stake in Axsome Therapeutics in the fourth quarter valued at approximately $300,000. Finally, HB Wealth Management LLC grew its stake in shares of Axsome Therapeutics by 136.7% during the fourth quarter. HB Wealth Management LLC now owns 34,102 shares of the company's stock worth $6,228,000 after buying an additional 19,696 shares during the last quarter. 81.49% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他大型投资者也买卖了该公司的股票。M&amp;T Bank Corp 在第四季度将其在 Axsome Therapeutics 的持股增加了 37.3%。M&amp;T Bank Corp 现在拥有 2,560 股公司股票，价值 467,000 美元，此前在上个季度又购买了 696 股。Pictet Asset Management Holding SA 在第四季度将其在 Axsome Therapeutics 的持仓增加了 20.4%。Pictet Asset Management Holding SA 现在拥有 436,063 股公司股票，价值 79,643,000 美元，此前在上个季度又购买了 73,925 股。UBS Group AG 在第四季度将其在 Axsome Therapeutics 的股份增加了 67.2%。UBS Group AG 现在拥有 355,318 股公司股票，价值 64,895,000 美元，此前在上个季度又购买了 142,867 股。Concurrent Investment Advisors LLC 在第四季度获得了 Axsome Therapeutics 的新股份，价值约为 300,000 美元。最后，HB Wealth Management LLC 在第四季度将其在 Axsome Therapeutics 的股份增加了 136.7%。HB Wealth Management LLC 现在拥有 34,102 股公司股票，价值 6,228,000 美元，此前在上个季度又购买了 19,696 股。81.49% 的股票由机构投资者和对冲基金持有。</p>
</div><p>Get <strong>Axsome Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Axsome Therapeutics</strong> 的提醒：</p>
</div><h2>Axsome Therapeutics News Roundup</h2>
<div class="lb-trans"><h2>Axsome Therapeutics 新闻汇总</h2>
</div><p>Here are the key news stories impacting Axsome Therapeutics this week:</p>
<div class="lb-trans"><p>以下是本周影响 Axsome Therapeutics 的关键新闻：</p>
</div><ul>
<li>Positive Sentiment: Strong commercial traction — Axsome reported Q1 product revenue of $191.2M, up ~57% year‑over‑year driven by AUVELITY and SUNOSI, which supports the company’s growth narrative and near‑term cash generation. Read More.</li>
<li>Positive Sentiment: Analyst optimism and price‑target lifts — multiple firms raised targets (notably Mizuho to $310, Wells Fargo to $255, Baird and others), and coverage remains skewed positive, which can support upside momentum and bid interest. Read More.</li>
<li>Neutral Sentiment: Management outreach scheduled — Axsome will participate in May investor conferences (including a BofA fireside chat), offering additional investor access but uncertain immediate impact. Read More.</li>
<li>Neutral Sentiment: Earnings detail and call transcript available — analysts are parsing the conference call and guidance implications; deeper read may resolve questions around sales cadence and expense trajectory. Read More.</li>
<li>Negative Sentiment: Profitability miss — GAAP EPS of ($1.26) missed consensus (~$0.85 loss), and negative margins/ROE highlight near‑term profitability and cost structure concerns despite revenue strength. Read More.</li>
<li>Negative Sentiment: Insider selling — COO Mark Jacobson disclosed sales (large blocks on May 4 and a smaller sale May 5), which may raise short‑term sentiment questions even though filers report remaining holdings. Read More.</li>
<li>Negative Sentiment: Durability concerns — some analysts/commentators question sequential product sales trends and achievability of peak revenue assumptions, which could temper multiple expansion absent clearer margin improvements. Read More.</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：强劲的商业吸引力——Axsome 报告第一季度产品收入为 1.912 亿美元，同比增长约 57%，得益于 AUVELITY 和 SUNOSI，这支持了公司的增长叙述和近期现金生成。阅读更多。</li>
<li>积极情绪：分析师乐观和目标价上调——多家机构提高了目标价（尤其是瑞穗证券至 310 美元，富国银行至 255 美元，贝尔德等），覆盖仍然偏向积极，这可以支持上涨势头和买入兴趣。阅读更多。</li>
<li>中性情绪：管理层外联安排——Axsome 将参加 5 月的投资者会议（包括美银的炉边聊天），提供额外的投资者接触，但不确定立即影响。阅读更多。</li>
<li>中性情绪：财报细节和电话会议记录可用——分析师正在解析电话会议和指导的影响；更深入的阅读可能会解决关于销售节奏和费用轨迹的问题。阅读更多。</li>
<li>消极情绪：盈利未达预期——GAAP 每股收益为（1.26 美元），未达到市场共识（约 0.85 美元的亏损），负毛利率/股本回报率突显了近期盈利能力和成本结构的担忧，尽管收入强劲。阅读更多。</li>
<li>消极情绪：内部人士出售——首席运营官 Mark Jacobson 披露了销售（5 月 4 日的大宗交易和 5 月 5 日的小额交易），这可能会引发短期情绪问题，尽管报告者表示仍持有股份。阅读更多。</li>
<li>消极情绪：耐久性担忧——一些分析师/评论员质疑连续产品销售趋势和峰值收入假设的可实现性，这可能会抑制多重扩张，除非有更明确的毛利改善。阅读更多。</li>
</ul>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>5 medical stocks growing earnings by triple digits</li>
</ul>
<div class="lb-trans"><ul>
<li>5 只医疗股票的收益增长超过三位数</li>
</ul>
</div><p>Several research firms recently weighed in on AXSM. Jefferies Financial Group raised their price objective on Axsome Therapeutics from $245.00 to $275.00 and gave the company a &#34;buy&#34; rating in a report on Monday. Cantor Fitzgerald reissued an &#34;overweight&#34; rating and set a $272.00 price target on shares of Axsome Therapeutics in a research note on Monday. Truist Financial raised Axsome Therapeutics to a &#34;strong-buy&#34; rating in a research note on Wednesday, March 25th. Oppenheimer set a $280.00 target price on shares of Axsome Therapeutics in a research report on Monday. Finally, Needham &amp; Company LLC boosted their target price on shares of Axsome Therapeutics from $225.00 to $255.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $251.26.</p>
<div class="lb-trans"><p>几家研究公司最近对 AXSM 发表了看法。Jefferies Financial Group 将 Axsome Therapeutics 的目标价从 245.00 美元上调至 275.00 美元，并在周一的报告中给予该公司 “买入” 评级。Cantor Fitzgerald 在周一的研究报告中重新发布了 “增持” 评级，并设定了 272.00 美元的目标价。Truist Financial 在 3 月 25 日的研究报告中将 Axsome Therapeutics 的评级提升至 “强力买入”。Oppenheimer 在周一的研究报告中设定了 280.00 美元的目标价。最后，Needham &amp; Company LLC 将 Axsome Therapeutics 的目标价从 225.00 美元上调至 255.00 美元，并在周二的报告中给予该股票 “买入” 评级。一位研究分析师给予该股票 “强力买入” 评级，十八位给予 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，共识目标价为 251.26 美元。</p>
</div><p><strong>View Our Latest Stock Report on AXSM</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 AXSM 股票报告</strong></p>
</div><h2>Axsome Therapeutics Trading Down 0.2%</h2>
<div class="lb-trans"><h2>Axsome Therapeutics 股价下跌 0.2%</h2>
</div><ul>
<li>Struggling Axsome Stock Could Bounce Back on Drug Trial Success</li>
</ul>
<div class="lb-trans"><ul>
<li>struggling Axsome 股票可能因药物试验成功而反弹</li>
</ul>
</div><p>NASDAQ:AXSM opened at $222.63 on Thursday. Axsome Therapeutics, Inc. has a 52 week low of $96.09 and a 52 week high of $234.29. The company has a debt-to-equity ratio of 2.27, a quick ratio of 1.48 and a current ratio of 1.39. The firm's fifty day moving average is $172.69 and its 200-day moving average is $164.03. The firm has a market cap of $11.46 billion, a P/E ratio of -59.69 and a beta of 0.59.</p>
<div class="lb-trans"><p>NASDAQ:AXSM 周四开盘价为 222.63 美元。Axsome Therapeutics, Inc.的 52 周低点为 96.09 美元，52 周高点为 234.29 美元。该公司的债务与股本比率为 2.27，速动比率为 1.48，流动比率为 1.39。该公司的 50 日移动平均线为 172.69 美元，200 日移动平均线为 164.03 美元。该公司的市值为 114.6 亿美元，市盈率为-59.69，贝塔值为 0.59。</p>
</div><p>Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its earnings results on Monday, May 4th. The company reported ($1.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.41). The firm had revenue of $191.20 million for the quarter, compared to the consensus estimate of $191.10 million. Axsome Therapeutics had a negative return on equity of 267.16% and a negative net margin of 26.59%.Axsome Therapeutics's revenue was up 57.4% compared to the same quarter last year. Equities analysts expect that Axsome Therapeutics, Inc. will post -1.19 earnings per share for the current year.</p>
<div class="lb-trans"><p>Axsome Therapeutics（NASDAQ:AXSM - 获取免费报告）最后一次公布财报是在 5 月 4 日，周一。该公司报告本季度每股收益为（1.26 美元），未达到分析师的共识预期（0.85 美元的亏损），差距为（0.41 美元）。该公司本季度的收入为 1.912 亿美元，而市场共识预期为 1.911 亿美元。Axsome Therapeutics 的股本回报率为负 267.16%，净利润率为负 26.59%。Axsome Therapeutics 的收入同比增长 57.4%。股票分析师预计 Axsome Therapeutics, Inc.在本年度将发布-1.19 的每股收益。</p>
</div><h2>Insider Transactions at Axsome Therapeutics</h2>
<div class="lb-trans"><h2>Axsome Therapeutics 的内部交易</h2>
</div><p>In other news, insider Ari Maizel sold 7,500 shares of the business's stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $182.42, for a total value of $1,368,150.00. Following the transaction, the insider directly owned 7,500 shares of the company's stock, valued at $1,368,150. The trade was a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Also, COO Mark L. Jacobson sold 35,378 shares of the company's stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $161.88, for a total value of $5,726,990.64. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 72,628 shares of company stock valued at $12,205,662. Corporate insiders own 20.60% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，内部人士 Ari Maizel 在 2023 年 4 月 22 日的交易中出售了 7,500 股公司的股票。股票的平均售价为 182.42 美元，总价值为 1,368,150.00 美元。交易后，该内部人士直接持有 7,500 股公司股票，价值为 1,368,150 美元。此次交易使其持股减少了 50.00%。该出售在向证券交易委员会提交的文件中披露，相关文件可通过此链接获取。此外，首席运营官 Mark L. Jacobson 在 2023 年 2 月 26 日的交易中出售了 35,378 股公司的股票。这些股票的平均售价为 161.88 美元，总价值为 5,726,990.64 美元。关于此次出售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士共出售了 72,628 股公司股票，价值为 12,205,662 美元。公司内部人士持有 20.60% 的公司股票。</p>
</div><h2>About Axsome Therapeutics</h2>
<div class="lb-trans"><h2>关于 Axsome Therapeutics</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.</p>
<div class="lb-trans"><p>Axsome Therapeutics, Inc 是一家临床阶段的生物制药公司，致力于开发针对中枢神经系统（CNS）疾病的新疗法。该公司专注于小分子药物，旨在满足抑郁症、偏头痛、嗜睡症和纤维肌痛等领域的未满足医疗需求。Axsome 采用精准医学的方法，利用药理创新来针对疾病的潜在机制，提高患者的治疗效果。</p>
</div><p>Axsome's pipeline includes several late-stage and approved product candidates.</p>
<div class="lb-trans"><p>Axsome 的产品管线包括多个晚期和已批准的产品候选者。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Axsome Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Axsome Therapeutics 更好的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AXSM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Axsome Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Axsome Therapeutics 吗？</h2>
</div><p>Before you consider Axsome Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Axsome Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Axsome Therapeutics 并不在名单上。</p>
</div><p>While Axsome Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Axsome Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Oppenheimer & Co. Inc. Takes $1.29 Million Position in Axsome Therapeutics, Inc. $AXSM

Market Beat

Axsome Therap

奥本海默控股

M&T Bank

瑞银集团

瑞穗金融集团

Mizuho Financial Group, Inc.

富国银行

美国银行

Jefferies Financial

Truist Financial

M & T BANK CORP DEP SHS REPSTG 1/400TH INT PERP SER K

M & T BANK CORP PERP NON CUM PFD FIXED FLTG RATE SER H

M & T BANK CORP DEP SHS EA REP 1/400TH SHS SERIES J

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Oppenheimer & Co. Inc. 在 Axsome Therapeutics, Inc. $AXSM 中建立了价值 129 万美元的头寸